STOCK TITAN

Akebia Therapeut - AKBA STOCK NEWS

Welcome to our dedicated page for Akebia Therapeut news (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeut stock.

Overview

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company headquartered in Cambridge, Massachusetts, dedicated to transforming lives by developing innovative therapies for patients affected by kidney disease. Specializing in chronic kidney disease and anemia treatment, Akebia leverages its deep expertise in hypoxia‐inducible factor (HIF) biology to create novel oral therapeutics that address unmet medical needs in renal care.

Core Business and Product Portfolio

At its core, Akebia Therapeutics focuses on the research, development, and commercialization of therapies aimed at improving outcomes for patients with kidney disease. The company’s diversified portfolio includes:

  • Auryxia (ferric citrate): A treatment approved and marketed in the United States for the control of serum phosphorus levels in dialysis-dependent patients and the treatment of iron deficiency anemia in non-dialysis patients with chronic kidney disease. This product underscores the company’s expertise in addressing mineral and iron imbalances in renal disease.
  • Vafseo (vadadustat): An investigational, once-daily oral HIF prolyl hydroxylase inhibitor. Vafseo is designed to mimic the body’s natural response to hypoxia, thereby stimulating the endogenous production of erythropoietin and effectively managing anemia in chronic kidney disease patients on dialysis. Approved in select territories and under extensive phase 3 clinical evaluation, Vafseo is positioned as a potential new oral therapeutic option for anemia treatment.
  • Preclinical HIF-PH Inhibitor Programs: Akebia is also advancing a pipeline of next-generation HIF inhibitors aimed at further expanding its therapeutic reach in kidney disease and related conditions.

Market Position and Strategic Collaborations

Akebia Therapeutics occupies a distinctive niche within the biopharmaceutical sector, combining innovative science with robust commercial capabilities. The company is actively engaged in multiple strategic initiatives:

  • Commercial Launch Initiatives: With a strong emphasis on enabling widespread access to its therapies, particularly Vafseo, Akebia is executing comprehensive launch strategies. The company’s commercial team collaborates closely with dialysis organizations and renal care providers to secure contracting agreements and ensure market penetration.
  • Regulatory Milestones: The company has achieved significant regulatory approvals in various regions. Notably, Vafseo has been approved in select markets and is under active review in others. These accomplishments demonstrate the regulatory robustness and clinical promise of its product portfolio.
  • Bidirectional Collaborations: Akebia’s collaborations with key industry partners, including large dialysis organizations and research institutions, reflect its commitment to building a sustainable ecosystem in renal care. These efforts enhance the company’s ability to drive prescriber demand and improve patient outcomes through scientific exchange and clinical evidence generation.

Clinical Evidence and Research Commitment

Central to Akebia Therapeutics’ strategy is its investment in clinical research. The company has conducted extensive phase 3 clinical trials to evaluate the safety and efficacy of its lead product candidates. Data emerging from studies such as the INNO2VATE and VOICE trials have fortified the company’s scientific foundation, demonstrating the potential of its HIF-PH inhibitor to effectively manage anemia. Akebia continues to engage the nephrology community through the dissemination of clinical data at major scientific conferences and via peer-reviewed publications, thereby reinforcing its commitment to evidence-based medicine.

Operational Excellence and Financial Stability

Akebia’s business model is underpinned by operational excellence and a strong financial foundation. The company’s strategic initiatives are carefully designed to support long-term operational stability, including robust cash management and targeted expense control. By leveraging innovative financing strategies and maintaining diversified revenue streams from its approved product, the company is well-positioned to fund its ongoing clinical development and commercial launch activities without relying on speculative financial performance metrics.

Expertise, Experience, and Trustworthiness

With a team of seasoned professionals in the fields of biotechnology, clinical research, and commercial operations, Akebia Therapeutics exemplifies the principles of Experience, Expertise, Authoritativeness, and Trustworthiness (E-E-A-T). The company’s leadership has a proven track record in navigating complex regulatory landscapes, executing clinical trials, and forging strategic partnerships. This collective expertise, combined with transparent communication and rigorous adherence to clinical standards, underscores Akebia’s commitment to delivering high-quality therapeutics in the kidney disease space.

Industry Impact and Future Endeavors

Although Akebia remains focused on its current portfolio, its impact on the biopharmaceutical landscape is significant. By providing innovative treatment options for chronic kidney disease and anemia, the company not only addresses immediate patient needs but also paves the way for future advancements in renal therapeutics. The integration of cutting-edge research with practical, market-oriented strategies has established Akebia as a trusted entity among healthcare providers, regulatory authorities, and patients alike.

Conclusion

Akebia Therapeutics is redefining the management of kidney disease through its innovative approach to anemia treatment and its strategic focus on HIF biology. Its comprehensive portfolio, deep industry expertise, and commitment to clinical excellence make it a key player in the evolution of renal care. By continuously investing in robust scientific research and fostering strategic collaborations, Akebia is setting new benchmarks in the development and commercialization of effective, patient-centric therapies.

Rhea-AI Summary
Akebia Therapeutics receives approval for Vafseo in Australia for the treatment of anemia in CKD patients on dialysis. Vadadustat achieved primary and secondary efficacy endpoints in clinical trials. Akebia plans to resubmit new drug application for vadadustat in the US. Akebia appoints Graham Ray as VP to lead customer engagement. Auryxia net product revenue guidance slightly lowered to $170-$175 million for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.54%
Tags
none
-
Rhea-AI Summary
Akebia Therapeutics, Inc. (Nasdaq: AKBA) will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11, 2023. The conference will be held in New York from September 11-13, 2023. The webcast of the presentation can be accessed through Akebia's website, with a replay available for approximately 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
conferences
-
Rhea-AI Summary
Akebia Therapeutics grants options to newly-hired employees as inducements
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
none
Rhea-AI Summary
Akebia reports Q2 2023 net product revenue of $42.2 million for Auryxia and reaffirms 2023 revenue guidance of $175.0-$180.0 million. Plans to resubmit NDA for vadadustat in Q3 2023. Akebia gains approval for vadadustat in 33 additional countries. Akebia enters exclusive license agreement with Medice. Net loss of $11.2 million for Q2 2023. Cash position of $53.6 million as of June 30, 2023. Akebia identifies accounting errors and material weakness in internal controls.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
-
Rhea-AI Summary
Akebia expects to resubmit NDA for vadadustat by Q3 2023, received productive meeting minutes with FDA
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
-
Rhea-AI Summary
Akebia to release Q2 financial results on August 25th and host conference call at 9:00 a.m. ET
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
conferences earnings
Rhea-AI Summary
Akebia Therapeutics, Inc. received a notice of non-compliance from Nasdaq for not timely filing its Form 10-Q. The company plans to release its financial results for Q2 2023 by August 25, 2023, and expects to regain compliance upon filing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.29%
Tags
none
-
Rhea-AI Summary
Akebia Therapeutics, Inc. granted its new Senior Vice President, Chief Financial Officer, and Treasurer, Ellen Snow, options to purchase 560,000 shares of the company's common stock at an exercise price of $1.67 per share. The options vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% vesting quarterly thereafter, subject to Ms. Snow's continued service with Akebia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.98%
Tags
none
Rhea-AI Summary
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced that CEO John Butler will participate in a fireside chat at the H.C. Wainwright 2nd Annual Kidney Conference to discuss recent regulatory updates regarding vadadustat, Akebia's oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia due to chronic kidney disease in adult patients on dialysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.98%
Tags
conferences

FAQ

What is the current stock price of Akebia Therapeut (AKBA)?

The current stock price of Akebia Therapeut (AKBA) is $1.91 as of April 1, 2025.

What is the market cap of Akebia Therapeut (AKBA)?

The market cap of Akebia Therapeut (AKBA) is approximately 414.5M.

What is the core focus of Akebia Therapeutics?

Akebia Therapeutics focuses on developing and commercializing innovative therapies for kidney disease, particularly treatments for anemia associated with chronic kidney disease using HIF biology.

Which products are part of Akebia's portfolio?

The company’s portfolio includes Auryxia (ferric citrate) for controlling serum phosphorus and treating iron deficiency anemia, and Vafseo (vadadustat), an oral HIF prolyl hydroxylase inhibitor for managing anemia in dialysis patients.

How does Vafseo work as a treatment?

Vafseo is designed as a once-daily oral tablet that activates the body’s natural response to hypoxia, thereby stimulating endogenous erythropoietin production to help manage anemia in patients with kidney disease on dialysis.

What distinguishes Akebia Therapeutics in the biopharmaceutical industry?

Akebia is distinguished by its integrated approach that combines rigorous clinical research, strong regulatory achievements, strategic collaborations with dialysis organizations, and a commitment to evidence-based innovation in renal care.

How does Akebia support its commercial launch strategies?

The company executes comprehensive launch strategies by partnering with major dialysis providers and securing contracting agreements, ensuring broad market access for its products and facilitating effective prescriber engagement.

What type of clinical research does Akebia undertake?

Akebia conducts extensive phase 3 clinical trials, including studies such as INNO2VATE and VOICE, to evaluate the safety and efficacy of its lead candidates like Vafseo, and regularly publishes findings at major scientific conferences.

What role does regulatory approval play in Akebia’s operations?

Regulatory approvals are central to Akebia’s business model, as they validate the safety and efficacy of its therapies. The company has secured approvals for Auryxia and is actively engaging with regulatory bodies for Vafseo across various markets.

How does Akebia demonstrate E-E-A-T in its business practices?

Akebia demonstrates E-E-A-T by maintaining a team of seasoned experts, investing in high-quality clinical research, achieving regulatory milestones, and fostering transparent, evidence-based communication with healthcare professionals and regulators.
Akebia Therapeut

Nasdaq:AKBA

AKBA Rankings

AKBA Stock Data

414.54M
232.73M
4.45%
28.9%
6.82%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
CAMBRIDGE